APTO - Aptose Biosciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.80
+0.05 (+0.87%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.75
Open5.71
Bid5.67 x 900
Ask6.07 x 1000
Day's Range5.57 - 5.94
52 Week Range1.81 - 9.25
Volume457,020
Avg. Volume1,050,184
Market Cap443.534M
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-0.52
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.89
  • GlobeNewswire

    Aptose Reports Results for the Fourth Quarter and Full Year 2019

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the year and three months ended December 31, 2019 and reported on corporate developments. Based on current operations, we expect that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into early 2022.

  • ACCESSWIRE

    Aptose Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Aptose Biosciences, Inc. (NASDAQ:APTO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at ...

  • GlobeNewswire

    Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

    SAN DIEGO and TORONTO, Feb. 25, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • Are Options Traders Betting on a Big Move in Aptose (APTO) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Aptose (APTO) Stock?

    Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

  • Steven Cohen Renews His Interest in Verastem
    GuruFocus.com

    Steven Cohen Renews His Interest in Verastem

    Guru invests in restructuring cancer drug developer Continue reading...

  • GlobeNewswire

    Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

    SAN DIEGO and TORONTO, Jan. 29, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • Top Ranked Momentum Stocks to Buy for January 29th
    Zacks

    Top Ranked Momentum Stocks to Buy for January 29th

    Top Ranked Momentum Stocks to Buy for January 29th

  • 5 'Strong Buy' Biotech Stocks to Buy for 2020
    Kiplinger

    5 'Strong Buy' Biotech Stocks to Buy for 2020

    Investors seeking out high growth for their portfolios will often turn to biotech stocks. The biotechnology industry, which has become densely populated as our understanding of living systems and organisms continues to expand, has earned a reputation on Wall Street for its explosive potential ... and high volatility.In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.Of course, there's a reason risk-averse investors shy away from these stocks: The opposite also holds true.Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.We used TipRanks' Stock Screener tool to comb through hundreds of biotechnology stocks to identify promising picks - ones that have received enough lopsided support from analysts that they earn TipRanks' top Strong Buy consensus rating. Here, we have found five top biotech stocks with overwhelmingly bullish sentiment from the analyst community, and price-growth projections of between 28% and 82%. SEE ALSO: 8 Stock Picks Getting Hit by Coronavirus Fears

  • Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Aptose (APTO) Stock?

    Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

  • GlobeNewswire

    Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference

    SAN DIEGO and TORONTO, Jan. 07, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • GlobeNewswire

    Aptose Announces Closing of Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase additional common shares in the Offering. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are approximately US$74.2 million.

  • Hedge Funds Have Never Been This Bullish On Aptose Biosciences Inc (APTO)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Aptose Biosciences Inc (APTO)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    Aptose Announces Pricing of Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are expected to be approximately US$64.5 million. The underwriters have been granted a 30-day option to purchase up to an additional 2,418,750 common shares in the Offering, under the same terms and conditions.

  • Benzinga

    The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

  • GlobeNewswire

    Aptose Announces Proposed Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the Underwriters a 30-day option to purchase up to an additional 15% of the common shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire

    Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

    SAN DIEGO and TORONTO, Dec. 09, 2019 -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics.

  • GlobeNewswire

    Aptose Presents Highlights From Corporate Event At ASH

    SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today.

  • GlobeNewswire

    Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

    Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Rafael Bejar, M.D., Ph.D., to the position of Senior Vice President, Chief Medical Officer, effective January 1, 2020. In his role as a member of the executive leadership team, Dr. Bejar will oversee global clinical development and regulatory initiatives for Aptose, as well as other research activities. “Rafael is a physician-scientist whose depth of experience both in the research setting and in treating patients with hematologic malignancies brings a unique and important perspective as we accelerate the clinical development of our hematologic product candidates,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

  • GlobeNewswire

    Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO and TORONTO, Dec. 02, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Aptose to Present at BIO-Europe Conference

    SAN DIEGO and TORONTO, Nov. 07, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • GlobeNewswire

    Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

    – Company to Hold Event During ASH –  – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 -- Aptose Biosciences Inc. (“Aptose”).

  • GlobeNewswire

    Aptose Reports Results for the Third Quarter Ended September 30, 2019

    CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical.

  • GlobeNewswire

    Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

    SAN DIEGO and TORONTO, Oct. 22, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target.

  • GlobeNewswire

    Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

    SAN DIEGO and TORONTO, Oct. 10, 2019 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.